Retroperitoneal leiomyosarcoma: a case report

Retroperitoneal leiomyosarcoma is a relatively rare and aggressive tumor. Because of its rarity, it is difficult to arrive at a definite diagnosis preoperatively and to design an effective strategy. Here the authors report a case of peritoneal leiomyosarcoma in which diagnosis was difficult because the clinical course resembled that of ovarian cancer. A 77-year-old woman diagnosed with ovarian cancer underwent laparotomy. The excised tumor contained a necrotic polypoid mass that histologically displayed the features of leiomyosarcoma. The patient received adjuvant chemotherapy with a combination of gemcitabine and docetaxel but died two months after surgery owing to the aggressive behavior of the tumor. Because the preoperative diagnosis in this case was ovarian cancer, arriving at a treatment strategy assuming peritoneal leiomyosarcoma was difficult. If complete surgical resection of tumor is not performed, as in the present case, the prognosis can be extremely poor.

Retroperitoneal; Leiomyosarcoma; Diagnosis.

[1] Adam Y.G., Oland J., Halevy A. Reif R.: “Primary retroperitoneal soft-tissue sarcomas”. J. Surg. Oncol., 1984, 25, 8.

[2] Cody H.S., Turnbull A.D., Fortner J.G., Hajdu S.I.: “The continuing challenge of retroperitoneal sarcomas”. Cancer, 1981, 47, 2147.

[3] McGrath P.C., Neifeld J.P., Lawrence W., DeMay R.M., Kay S., Horsley J.S. 3rd, Parker G.A.: “Improved survival following complete excision of retroperitoneal sarcomas”. Ann. Surg., 1984, 200, 200.

[4] Catton C.N., O`Sullivan B., Kotwall C., Cummings B., Hao Y., Fornasier V.: “Outcome and prognosis in retroperitoneal soft tissue sarcoma”. Int. J. Radiat. Oncol. Biol. Phys., 1994, 29, 1005.

[5] Todd C.S., Michael H., Sutton G.: “Retroperitoneal leiomyosarcoma: eight cases and a literature review”. Gynecol. Oncol., 1995, 59, 333.

[6] Kransdorf M.J.: “Malignant soft-tissue tumors in a large referral population: distribution of diagnoses by age, sex, and location”. Am. J. Roentgenol., 1995, 164, 129.

[7] Storm F.K., Mahvi D.M.: “Diagnosis and management of retroperitoneal soft-tissue sarcoma”. Ann. Surg., 1991, 214, 2.

[8] Biswajit D., Parth D., Richa G., Nita K., Gauri G.: “Primary leiomyosarcoma of peritoneal cavity”. Rare Tumors, 2014, 6, 5165.

[9] Toulmonde M., Bonvalot S., Méeus P., Stoeckle E., Riou O., Isambert N., et al.: “French Sarcoma Group. Retroperitoneal sarcomas: patterns of care at diagnosis, prognostic factors and focus on main histological subtypes: a multicenter analysis of the French Sarcoma Group”. Ann. Oncol., 2014, 25, 735.

[10] Trans-Atlantic RPS Working Group: “Management of primary retroperitoneal sarcoma (RPS) in the adult: a consensus approach from the Trans-Atlantic RPS Working Group”. Ann. Surg. Oncol., 2015, 22, 256.

[11] Dull B.Z., Smith B., Tefera G., Weber S.: “Surgical management of retroperitoneal leiomyosarcoma arising from the inferior vena cava”. J. Gastrointest. Surg., 2013, 17, 2166.

[12] Gemici K., Buldu I., Acar T., Alptekin H., Kaynar M., Tekinarslan E., et al.: “Management of patients with retroperitoneal tumors and review of the literature”. World J. Surg. Oncol., 2015, 13, 143.

[13] Allen M.M., Douds J.J., Liang S.X., Desouki M.M., Parkash V., Fadare O.: “An immunohistochemical analysis of stahmin 1 expression in uterine smooth muscle tumors: differential expression in leiomyosarcomas and leiomyomas”. Int. J. Clin. Exp. Pathol., 2015, 8, 2795.

[14] Mateo Vallejo F., Dominguez Reinado M.R., Medina Achirica C., Diaz Oteros M., Esteban Ramos J.L., Melero Brenes S.: “Giant retroperitoneal leiomyosarcoma. Multiorgan block removal”. Int. J. Surg. Case Rep., 2014, 5, 1050.

[15] Duffaud F., Ray-Coquard I., Salas S., Pautier P.: “Recent advances in understanding and managing leiomyosarcomas”. F1000Prime Rep., 2015, 7, 55.

[16] Hensley M.L., Maki R., Ventatramen E., Geller G., Lovegren M., Aghajanian C., et al.: “Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial”. J. Clin. Oncol., 2002, 20, 2824.

[17] Hensley M.L., Blessing J.A., Mannel R., Rose P.G.: “Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma. a Gynecologic Oncology Group phase II trial”. Gynecol. Oncol., 2008, 109, 329.